EUCTR2009-012258-19-BE进行中（未招募）不适用
A Multicentre, Open-label, Pharmacokinetic Study of Modigraf® (Tacrolimus granules) in de novo Paediatric Allograft Recipients. - OPTION study
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The subject is 12 years of age or younger.
- •2. The subject is the recipient of a solid organ (liver, kidney or heart) transplant. Multiorgan transplants are acceptable as long as one of the organs transplanted is liver, kidney or heart.
- •3. The subject’s parent(s) or their legal representative(s) has been fully informed and has given written informed consent to participate in the study. The subject has given assent where applicable.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 60
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. The subject has previously received another organ transplant (including liver, kidney or heart re-transplantation).
- •2. Subject has a high immunological risk, defined as a Panel Reactive Antibody (PRA)
- •score >50% in the previous 6 months (only applicable for renal transplant recipients).
- •3. Cold ischemia time of the donor kidney greater than 30 hours (only applicable for renal transplant recipients).
- •4. Subject receives an AB0 incompatible donor organ.
- •5. Subject has significant renal impairment, defined as having serum creatinine =230
- •µmol/l (=2.6 mg/dl) pre-transplantation (not applicable for renal transplant recipients).
- •6. Subject has significant liver disease, defined as having elevated ALT and/or AST and/or Total Bilirubin levels 3 times the upper value of the normal range during the 28 days prior to transplantation (not applicable for liver transplant recipients).
- •7. Subject with pulmonary vascular resistance greater than 4 Wood units which is
- •unresponsive to treatment.
- •8. Subjects with malignancies or a history of malignancy within the last 5 years.
- •9. Subject has a significant, uncontrolled systemic infection and/or severe diarrhea,
- •vomiting, active upper gastrointestinal disorder that may affect the absorption of
- •tacrolimus or has an active peptic ulcer.
- •10. Subject requires systemic immunosuppressive medication for any indication other than transplantation.
- •11. Recipient or donor known to be HIV, HCV or HBV positive.
- •12. Known allergy or intolerance to steroids, macrolide antibiotics, basiliximab or tacrolimus.
- •13. Subject is currently participating in another clinical trial and/or has been taking an
- •investigational drug in the 3 months prior to transplantation.
- •14. Subject is unlikely to comply with the visits scheduled in the protocol.
- •15. Subjects taking or requiring to be treated with medication or substances prohibited by this protocol.
研究者
相似试验
进行中（未招募）
1 期
A study to determine the uptake, distribution and removal of the active ingredient tacrolimus from the body in children with newly transplanted organs after taking Modigraf (tacrolimus-containing medicine in the form of granules that can be suspended in fluid).De novo allograft transplantation (liver, heart, kidney) in paediatric patients.MedDRA version: 18.0Level: PTClassification code 10019314Term: Heart transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10024716Term: Liver transplantationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2009-012258-19-FRAstellas Pharma Europe Ltd.36
进行中（未招募）
不适用
A study of an approved granule formulation of tacrolimus to examine the absorption and excretion by the body of newly transplanted paediatric patientsDe novo allograft transplantation (liver, heart, kidney) in paediatric patients.MedDRA version: 14.1Level: PTClassification code 10019314Term: Heart transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: LLTClassification code 10024716Term: Liver transplantationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2009-012258-19-DEAstellas Pharma Europe Ltd.60
进行中（未招募）
1 期
A Multicentre, Open-label, Pharmacokinetic Study of Modigraf® (Tacrolimus granules) in de novo Paediatric Allograft Recipients. - OPTION Version 1.0EUCTR2009-012258-19-GBAstellas Pharma Europe Ltd.52
进行中（未招募）
不适用
A Multicentre, Open-label, Pharmacokinetic Study of Modigraf® (Tacrolimus granules) in de novo Paediatric Allograft Recipients.Estudio Abierto, Multicéntrico, Farmacocinético de Modigraf® (Tacrólimus Granulado para suspensión oral) en pacientes pediátricos que reciben un aloinjerto de novo. - OPTION studyDe novo allograft transplantation (liver, heart, kidney) in paediatric patients. Pacientes pediátricos que reciben un trasplante de aloinjerto de novo ( hígado, corazón y riñón)MedDRA version: 13.1Level: LLTClassification code 10024716Term: Liver transplantationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 13.1Level: PTClassification code 10019314Term: Heart transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 13.1Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2009-012258-19-ESAstellas Pharma Europe Ltd.36
已完成
不适用
A multi-center, open-label, pharmacokinetic study of oral nilotinib in pedriatric patients with Gleevec (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL.;Met protocol amendment #03 verandert de titel als volgt: *A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with newly diagnosed chronic phase (CP) Ph+ CML, with CP or accelerated phase (AP) Ph+ CML resistant/intolerant to imatinibChronic Myeloid Leukemia and Philadelphia chromosome positive acute Lymphoblastic Leukemia10024324NL-OMON39198ovartis3